Another MS Drug Class Causes Concern for COVID Vaccine Protection

(MedPage Today) -- Multiple sclerosis (MS) patients treated with cladribine (Mavenclad) or teriflunomide (Aubagio) had appropriate humoral response against SARS-CoV-2 a month after vaccination, but those treated with anti-CD20 therapies or sphingosine...